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Abstract
Background
Atopic dermatitis (AD) is a complex chronic inflammatory disease where allergens can act
as specific triggering factors.
Aim
To characterize the specificities of IgE-reactivity in patients with AD to a broad panel of
exogenous allergens including microbial and human antigens.
Methodology
Adult patients with AD were grouped according to the SCORAD index, into severe (n = 53)
and moderate AD (n = 126). As controls 43 patients were included with seborrhoeic eczema
and 97 individuals without history of allergy or skin diseases. Specific IgE reactivity was
assessed in plasma using Phadiatop1, ImmunoCap™, micro-arrayed allergens, dot-blotted
recombinantMalassezia sympodialis allergens, and immune-blotted microbial and human
proteins.
Results
IgE reactivity was detected in 92% of patients with severe and 83% of patients with moder-
ate AD. Sensitization to cat allergens occurred most frequently, followed by sensitization to
birch pollen, grass pollen, and to the skin commensal yeastM. sympodialis. Patients with
severe AD showed a significantly higher frequency of IgE reactivity to allergens like cat
(rFel d 1) and house dust mite (rDer p 4 and 10), to Staphylococcus aureus,M. sympodialis,
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and to human antigens. In contrast, there were no significant differences in the frequencies
of IgE reactivity to the grass pollen allergens rPhl p 1, 2, 5b, and 6 between the two AD
groups. Furthermore the IgE reactivity profile of patients with severe AD was more spread
towards several different allergen molecules as compared to patients with moderate AD.
Conclusion
We have revealed a hitherto unknown difference regarding the molecular sensitization pro-
file in patients with severe and moderate AD. Molecular profiling towards allergen compo-
nents may provide a basis for future investigations aiming to explore the environmental,
genetic and epigenetic factors which could be responsible for the different appearance and
severity of disease phenotypes in AD.
Introduction
Atopic dermatitis (AD) is a complex chronic inflammatory skin disease with 15–30% of chil-
dren and 2–10% of adults being afflicted [1]. The pathogenesis of AD is considered to result
from a combination of a defective skin barrier and inappropriate immune responses with con-
tribution of both genetic and environmental factors including microbial agents [2–4]. Allergens
are important in the pathogenesis of AD since they can act as specific trigger factors. For exam-
ple, exacerbations of AD can be observed in patients during allergen exposure[5] or upon
ingestion of allergen-containing food [6]. AD has according to the presence or to the absence
of detectable allergen-specific IgE antibodies been classified into either an extrinsic or an
intrinsic type [7]. Still, another subgroup of patients with AD has an autoimmune IgE-medi-
ated reactivity against auto-antigens in addition to sensitization against exogenous allergens
[8,9].
In addition microorganisms play a role in eliciting and maintaining eczema in patients with
AD [10]. One such microorganism isMalassezia, a commensal yeast that dominates the
human fungal skin flora[11] but is also associated with a number of skin disorders, such as
seborrhoeic eczema (SE), dandruff and AD [12].Malassezia sympodialis is one of the most fre-
quently isolated species from the skin of both AD patients and healthy individuals [13,14].
Allergen specific IgE- and T-cell reactivity and/or positive atopy patch test reaction toM. sym-
podialis can be detected in around 50% of adult patients with AD[12]. These reactions are
rarely found in other allergic diseases or skin disorders indicating a specific link between AD
andMalassezia in a subset of patients [15]. So far there are 10M. sympodialis allergens, desig-
nated Mala s 1 and Mala s 5–13, cloned, sequenced and characterized [16–22]. Four of the
allergens lack homology to known proteins, whereas others have cross-reactivity to human
homologues such as manganese superoxide dismutase [19] and thioredoxin [21]. The unique-
ness of these allergens makes them highly interesting as diagnostic tools and to understand sen-
sitization and cross-reactivity to human homologous antigens in AD.
There are several techniques for determining IgE sensitizations such as allergen-specific
IgE serology, skin prick test, and when necessary oral food challenges. By introducing new
methodologies for phenotype characterization of patients with AD it may be possible to
develop personalized strategies for prevention and management to break, terminate or reverse
the natural course of this chronic disease. One way of achieving this goal could be using
micro-arrayed allergen molecules which allow measuring IgE reactivities in only a few
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microliters of serum or plasma to large panels of purified allergen molecules to identify dis-
ease-causing allergens [23,24].
In this study we sought to perform a meticulous analysis of the IgE-reactivity profiles in AD
patients with different severity to obtain information if and how molecular IgE sensitization
profiles towards a comprehensive set of exogenous, microbial and endogenous allergens may
be linked with different clinical phenotypes of AD including co-morbidity with respiratory
symptoms.
Materials and Methods
Study population
All subjects (n = 319) were recruited from the Stockholm area and examined by a dermatolo-
gist at the Dermatology and Venereology Unit, Karolinska University Hospital Stockholm,
Sweden, during September until May to avoid the summer season. Patients with a clinical diag-
nosis of AD or SE and healthy controls were included in the study (Table 1). Inclusion criteria
for AD patients were diagnosis according to the UK working party [25], moderate to severe
eczema, and skin lesions not only restricted to the hands. The severity of the eczema was
assessed using the objective SCORAD index [26] and present or patient reported head and
neck distribution was recorded. Exclusion criteria for the patients were other skin diseases than
AD or SE, immune deficiencies, autoimmune diseases and ongoing malignant diseases. The
history of patients reported respiratory allergic symptoms was documented as co-morbidity.
The healthy controls were subjects who did not have clinical symptoms or history of allergy or
skin disease. The study was approved by the Regional Ethical Review Board in Stockholm and
all participants gave their written informed consent.
Preparation of protein/allergen extracts
M. sympodialis (ATCC strain 42132) and human A431 epithelial cell extracts were prepared as
previously described [8,27]. Staphylococcus aureus (ATCC 25923) was grown overnight in
tryptic soy broth at 37°C and harvested by centrifugation at 3220 x g. The cells were washed
twice with phosphate-buffered saline (PBS) and inactivated by boiling for 10 min. The cell pel-
let was re-suspended in PBS and homogenized using an Ultra Turrax (IKA Labortechnik, Stau-
fen, Germany) and stored at -20°C until use.
Recombinant allergens
Recombinant Mala s 1, rMala s 5–13 (S1 Table) were expressed in Escherichia coli BL21 (DE3)
as his-tagged proteins and purified by inclusion body preparation and Ni2+-chelate chromatog-
raphy [16–21]. Purity of proteins was assessed by SDS-PAGE and Coomassie Blue staining
[28]. Protein concentrations were determined by Micro BCA Protein Assay (Pierce, Rockford,
IL).
IgE serology
Total IgE, specific IgE to any of 11 common aeroallergen sources (Phadiatop1) andM. sympo-
dialis-specific IgE (m70,) were measured in plasma using ImmunoCAP™ (Phadia AB, Uppsala,
Sweden).
For non-denaturing RAST-based dot blot assays, 0.2 μg purified recombinant allergens
were dotted onto nitrocellulose membrane strips (Schleicher&Schuell, Dassel, Germany) and
tested for IgE-reactivity with 125I-labelled anti-human IgE antibodies (Demeditec Diagnostics,
Kiel, Germany) [29]. For IgE immunoblot assays, comparable amounts (50 μg protein extract
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per centimeter slot of the preparative gel) ofM. sympodialis, human A431 epithelial cell line or
S. aureus extracts were boiled for 5 min with sodium dodecyl sulphate (SDS) sample buffer
containing 5% v/v beta-mercaptoethanol, subjected to 12.5% SDS-PAGE and blotted onto
nitrocellulose membranes [30,31]. A protein molecular weight marker (PageRuler prestained
Protein Ladder Plus, Fermentas, St Leon-Rot, Germany) was used as standard. To define a cut-
off for a positive/negative dot blot and immunoblot result human serum albumin (HSA) and
serum from non-allergic patients were used for control purposes. In every experiment three
sera from AD patients containing specific IgE to S. aureus,M. sympodialis and the human
extract were included as positive control.
IgE-reactivity to 120 micro-arrayed allergen components was analyzed with a customized
allergen-chip (Phadia Multiplexing, Thermo Fisher Scientific, Vienna, Austria) as previously
described [24].
Statistical analyses
Descriptive statistics and group comparisons were computed using IBM SPSS Statistics, version
22 (IBM Corp., Armonk, NY, USA). For comparison of the two groups of patients suffering
from moderate or severe AD, respectively, with respect to frequencies of reactivities to bacterial,
yeast and human antigens and to micro-arrayed allergen molecules, two-sided asymptotic p-val-
ues were calculated by Chi-square test. P-values 0.05 were considered statistically significant.
Results
Demographic and clinical characterization of AD patients and controls
The 179 AD patients (56% females) had a median age of 28 years (range 18–65 years)
(Table 1). According to SCORAD 53 patients (30%) suffered from severe AD and 156 patients
(87%) had present (n = 143) or previous (n = 13) head and neck distribution of their eczema.
Debut of the eczema was similar in both groups; in the majority of the AD patients the debut
Table 1. Demographic and clinical characterization of AD patients and controls.
Gender F / M Age
(years)
SCORAD a) Head and
neck
distribution
Rhino-
conjunctivitis
and/or asthma
Total
plasma IgE
b) 122
kU/L
Total
plasma IgE
b) (kU/L)
Phadiatop1
positive c)
n n median
(range)
median
(range)
n (%) N (%) N (%) median
(range)
n (%)
AD patients 179 101/ 78 28 (18–
65)
34 (14–70) 156 (87) 144 (80) 102 (57) 175 (2–
15100)
140 (78)
Severe a) 53 19 / 34 30 (18–
65)
54 (41–70) 48 (91) 48 (91) 38 (72) 480 (2.5–
15100)
46 (87)
Moderate a) 126 82/ 44 28 (18–
65)
31 (14–40) 108 (85) 96 (76) 64 (51) 130 (2–
6810)
94 (75)
SE patients 43 9 / 34 39 (18–
63)
NA NA 9 (21) 4 (9) 22 (2–390) 8 (19)
Healthy
controls
97 59 / 38 35 (18–
65)
NA NA 0 (0) 5 (5) 21 (2–230) 9 (9)
a) Objective SCORAD [26], severe AD deﬁned as SCORAD 41
b) ImmunoCAP™ (Phadia AB), reference range 1.6–122 kU/L
c) Phadiatop1 (Phadia AB), plasma IgE to any of 11 common aeroallergens, reference range  0.35 kU/L
AD = atopic eczema, F = Female, M = Male, n = number of positive individuals, NA = not applicable, SE = seborrhoeic eczema
doi:10.1371/journal.pone.0156077.t001
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was during the first year (58% in the severe group and 57% in the moderate group) and 17%
and 22%, respectively, after 5 years of age. The majority of AD patients (i.e., 144, 80%), had
ever had rhino-conjunctivitis and/or asthma in addition to AD (i.e., 91% in the severe and 76%
in the moderate AD group) whereas only 21% of the SE patients reported respiratory symp-
toms (Table 1).
Total plasma IgE levels were elevated (>122 kU/L) in 57% of the patients, with higher
median IgE levels in the severe AD group (480 kU/L) than in the moderate AD group (130 kU/
L) (Table 1). Seventy-eight % of the AD patients had a positive Phadiatop1 with a higher per-
centage among the severe AD patients (87%) in comparison to the moderate AD patients
(75%) (Table 1). Nine % of 43 individuals with SE had a total serum IgE level>122 kU/L and
19% had a positive Phadiatop1 (Table 1). Five % of the healthy controls (n = 97) had IgE levels
higher than 122 kU/L and for 9% the Phadiatop1 was positive (Table 1).
IgE reactivity to bacterial (S. aureus), yeast (M. sympodialis) and human
antigens was significantly more frequent in the severe AD group
IgE reactivity to nitrocellulose-blotted S. aureus,M. sympodialis and human antigens (epithelial
cell-line A431) was analyzed using plasma samples from all 179 AD patients, 43 SE patients
and 97 healthy controls. Twenty-one percent of the AD patients showed reactivity to antigens
in the S. aureus extract (i.e., 34% in the severe AD group compared to 16% in the moderate AD
group, p<0.01 (Table 2). Eighteen percent of the AD patients showed IgE reactivity to the
human cell extract. Again the percentage of reactivity was significantly higher (i.e., 30%) in
severe than in moderate AD patients (i.e., 13%) (p<0.01) (Table 2).
Likewise, IgE reactivity against theM. sympodialis extract was detected significantly more
often in severe (i.e., 60%) compared to moderate AD patients (i.e., 39%) with 45% of the 179
AD patients being positive on average (p<0.01) (Table 2). In addition, specific IgE toM. sym-
podialis was assessed with the ImmunoCap™ assay where 47% of the 179 AD patients, 62%
with severe and 41% with moderate eczema (p<0.01) (Table 2 and S1A–S1C Fig), whereas
none of the SE patients (Table 2) or healthy controls was positive in this assay (S2 Table). The
median specific plasma IgE levels againstM. sympodialis of the severe AD patients was 7.5 kU/
L and of the moderate AD patients 6.7 kU/L (Table 2). The majority, 98% (n = 156) of AD
patients with IgE reactivity toM. sympodialis had present or reported head and neck involve-
ment (S2 Table). Notably, 8% in the group of 53 severe AD patients had a negative Phadiatop1
reaction, not elevated total serum IgE and no detectable IgE antibodies toM. sympodialis, m70
(S1B Fig), and among the 126 patients with moderate AD the corresponding figure was 19%
(S1C Fig). There was a good agreement of results obtained with the immunoblot and Immuno-
CAP™ technology, only slightly higher positive results were observed with the CAP assay com-
pared to the immunoblotting method (AD 47% compared to 45%, severe AD 62% versus 60%,
moderate AD 41% versus 39%, Table 2).
No IgE-binding to S. aureus or human A431 extract was observed among the 43 SE patients,
but one of them who was Phadiatop1 positive, showed a weak IgE reactivity to one band in the
M. sympodialis extract (Table 2). None of the 97 healthy controls was positive in these assays.
We then performed an analysis of IgE reactivity to a set of 10 purified, recombinant Mala s
allergens (Mala s 1, Mala s 5–13, S1 Table) using a non-denaturing, RAST-based dot blot assay
(Table 2). IgE-reactivity to the different rMala s allergens varied between 2–30% among the
AD patients, with higher percentages for each of the allergens in the severe AD group (Table 2)
and with 4–67% IgE-reactivity among the AD patients ImmunoCAP™ or immunoblot positive
to theM. sympodialis extract (S2 Table). When reactivity to any of the 10 rMala s allergens was
summarized 44% of all AD patients were detected yielding an almost equal sensitivity as the
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allergen extract-based ImmunoCAP™ (47%) or Immunoblot assay (45%) (Table 2). IgE-reactiv-
ity to rMala s 7 was significantly more frequently detected in severe compared to moderate AD
patients (p<0.01, Table 2). rMala s 13 showed IgE reactivity in 38% of the severe and 27% of
the moderate AD patients, respectively, and was the most frequently detected Mala s allergen
(Table 2). Among the 85M. sympodialis ImmunoCAP™ positive AD patients 52 of them (61%)
reacted to rMala s 13 (S2 Table), therefore to be considered as a major allergen.
Only 1 patient with SE showed IgE reactivity to rMala s 11 (Table 2) and one healthy control
to rMala s 13 (S2 Table).
A limited number of allergen sources contribute to a different extent to
sensitization in severe and moderate AD patients
Using the allergen chip [24] with 120 allergen components (S3 Table), 82% of the 179 AD
patients showed IgE reactivity to at least one allergen, 85% of the severe and 80% of the moderate
Table 2. Frequencies of allergen-specific IgE reactivities in the AD and SE patients as tested by MeDALL allergen chip, Immunoblotting, Immuno-
CAP™ and RAST-based dot-blot assay.
All AD Severe AD Moderate AD SE patients
Method and allergen n = 179 n = 53 n = 126 n = 43
n (%) n (%) n (%) n (%)
MeDALL allergen chip positivea) n (%) 146 (82) 45 (85) 101 (80) 10 (23)
Immunoblot extracts
S. aureus positiveb) n (%) 38 (21) 18 (34) **g) 20 (16) 0 (0)
A431 positivec) n (%) 32 (18) 16 (30) ** 16 (13) 0 (0)
M. sympodialis positived) n (%) 81 (45) 32 (60) ** 49 (39) 1 (2)
ImmunoCAP™
M. sympodialis positivee) n (%) 85 (47) 33 (62) ** 52 (41) 0 (0)
Median (range) kU/L within positive individuals 6.7 (0.44–230) 7.5 (0.44–68) 6.7 (0.47–230) -
Dot-Blot, rMala s allergens positive n (%)
rMala s 1 18 (10) 6 (11) 12 (10) 0 (0)
rMala s 5 27 (15) 9 (17) 18 (14) 0 (0)
rMala s 6 28 (16) 11 (21) 17 (13) 0 (0)
rMala s 7 25 (14) 13 (25) ** 12 (10) 0 (0)
rMala s 8 4 (2) 2 (4) 2 (2) 0 (0)
rMala s 9 11 (6) 6 (11) 5 (4) 0 (0)
rMala s 10 21 (12) 9 (17) 12 (10) 0 (0)
rMala s 11 28 (16) 12 (23) 16 (13) 1 (2)
rMala s 12 14 (8) 6 (11) 8 (6) 0 (0)
rMala s 13 54 (30) 20 (38) 34 (27) 0 (0)
Any rMala sf) 78 (44) 31 (59) 47 (37) 1 (2)
a) MeDALL allergen chip, positive  0.30 ISU
b) Staphylococcus aureus ATCC 25923 extract
c) A431 Human epithelial cell line extract
d) Malassezia sympodialis ATCC 42132 extract
e) ImmunoCAP™ (Phadia AB), Malassezia sympodialis ATCC 42132 extract (m70), positive 0.35 kU/L
f) Individuals positive to one or more of the tested rMala s allergens
g) Signiﬁcant differences between severe and moderate AD patients are indicated ** p<0.01
AD = atopic dermatitis, SE = seborrhoeic eczema
doi:10.1371/journal.pone.0156077.t002
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AD patients were positive, respectively, and 23% of the 43 patients with SE showed IgE-reactivity
to micro-arrayed allergens (Table 2).
Fig 1A shows a pie chart representation of the contribution of different allergen sources to
IgE sensitization in severe and moderate AD patients. The chart was constructed based on the
frequencies of IgE sensitizations towardsM. sympodialis, S. aureus and human cell extracts
detected with immunoblotting (Table 2) and based on IgE-reactivity profiles towards 25 spe-
cific allergen components determined with micro-arrayed allergen molecules (Table 3 and S3
Table). As mentioned above the IgE sensitization toM. sympodialis, S. aureus and human anti-
gens contributed significantly more to IgE sensitization in severe versus moderate AD (p<0.01,
Table 2). IgE sensitization to genuine cat allergens (rFel d 1 and/or rFel d 4) and house dust
mite allergens (nDer p 1 and/or rDer p 2, rDer p 4, rDer p 5, rDer p 7, rDer p 10, rDer p 11,
rDer p 14, rDer p 15, rDer p 18, rDer p 21, rDer p 23) also contributed more to IgE sensitiza-
tion in severe versus moderate AD (Fig 1A). Birch pollen (rBet v 1) and mugwort (nArt v 1)
contributed equally to IgE sensitization in severe and moderate AD but interestingly, the con-
tribution of IgE sensitization to grass pollen (rPhl p 1 and/or rPhl p 2, rPhl p 5b, rPhl p 6) and
dog allergens (rCan f 1 and/or rCan f 2, rCan f 4, rCan f 5, rCan f 6) was less in severe as com-
pared to moderate AD (Fig 1A). IgE sensitization to other allergen sources was quite rare (S3
Table). Only 10% of all AD patients showed IgE reactivity to latex allergens (rHev b 6.01) and
2% to the mould Alternaria alternata (rAlt a 1). IgE reactivities to recombinant food allergens,
e.g., apple (rMal d 1, 42%), peach (rPru p 1, 18%), hazelnut (rCor a 1.0401, 34%) or soy (rGly
m 4, 16%) were due to IgE cross-reactivity to the major birch pollen allergen Bet v 1 (52%) (S3
Table). Other plant-derived food allergens, e.g., hazelnut (rCor a 8), kiwi allergens (nAct d 1,
nAct d 5) or wheat allergens (rTri a 19.0101) were recognized by only 4%, or less of the AD
patients. IgE to animal-derived food allergens could be detected in only a small percentage of
the AD patients, e.g., 7% of all AD patients showed IgE reactivity to egg allergens and cow`s
milk allergens were recognized by 2% of the patients. The frequencies of IgE reactivity to each
of the individual micro-arrayed allergens are reported in S3 Table.
In the group of 43 SE-patients, 14% showed IgE-reactivity to birch pollen (rBet v 1), 14% to
grass pollen (rPhl p 1), 5% to house dust mite (rDer p 2) and 2% to dog allergens (rCan f 1) (S3
Table). Plasma samples from 12 Phadiatop1 negative healthy controls were tested for control
purposes and they were all negative (S3 Table).
Selective spreading in the molecular sensitization profiles of severe as
compared to moderate AD patients
The frequencies of IgE reactivity to the individual allergen molecules are shown in Table 3 for
the most frequently recognized allergen sources and for each of the tested components in S3
Table. For most of the allergens we observed that they were recognized more frequently by
patients with severe as compared to patients with moderate AD (Table 3, S2A, S2B and S2D–
S2H Fig). For certain allergens (e.g. rFel d 1, rDer p 4, and rDer p 10) a significantly (p<0.05)
more frequent IgE recognition was found for the severe AD patients (Table 3). Interestingly,
genuine grass pollen allergens (i.e., rPhl p 1, rPhl p 2, rPhl p 5b, and rPhl 6) did not follow this
trend because they were recognized with a similar frequency in both patient groups (Table 3,
S2C Fig). Only the cross-reactive carbohydrate marker allergen from grass pollen (i.e., nPhl p
4) was more frequently recognized by severe AD patients (p<0.05, Table 3, S2C Fig). The same
pattern was observed when the patients were grouped into severe and moderate AD with
patient reported history of respiratory allergic symptoms, with the exception that a significant
difference (p<0.05) was reached for a higher IgE reactivity to rPhl p 2 in the moderate AD
patients compared to the severe AD patients (Table 3).
IgE Profiles in Atopic Dermatitis
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Fig 1. Pie charts showing the contribution of (A), allergen sources and (B), individual allergen components to IgE sensitization. Each
chart represents 100% of IgE reactivities detected in plasma from all AD patients of the respective group, severe AD (left chart) and moderate AD
(right chart), in (A) to six allergen sources using the MeDALL allergen-chip (ISU 0.3) and to extracts ofM. sympodialis, S. aureus and the human
cell line A431 using immunoblotting, and in (B) to 25 allergen molecules using the MeDALL allergen-chip (ISU 0.3). The sizes of the segments
represent the proportion of the respective in (A), allergen source and in (B), allergen molecule among all recognized. Allergen sources/molecules
start a 12 o’clock of the pie chart and continue clock-wise as listed with the color code.
doi:10.1371/journal.pone.0156077.g001
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Table 3. Frequencies and intensities of IgE reactivity to purifiedmarker allergens in AD patients detected by allergen chip technology.
No. Allergen All AD Severe
AD
Moderate
AD
Severe AD Moderate AD Allergen family,
Function, CCD
Severe AD Moderate AE
median
(range)
median
(range)
Rhinoconjuctivitis Rhinoconjuctivitis
n = 179 n = 53 n = 126 IgE (ISU)a) IgE (ISU) and/or asthma and/or asthma
n (%) n (%) n (%) n = 47 n (%) n = 96 n (%)
1 rFel d 1 93 (52) 36 (68) ** 57 (45) 4.3 (0.31–
134.17)
4.14 (0.35–
127.92)
Uteroglobin 36 (77) ** 51 (53)
2 rBet v 1 93 (52) 33 (62) 60 (48) 12.83 (0.33–
120.37)
8.96 (0.34–
102.94)
PR-10 32 (68) 51 (53)
3 rPhl p 1 79 (44) 24 (45) 55 (44) 2.11 (0.31–
48.74)
2.43 (0.31–
56.91)
β-Expansin 23 (49) 45 (47)
4 nPhl p 4 51 (29) 22 (42) * 29 (23) 1.53 (0.31–
16.6)
1.25 (0.39–
26.31)
Grass-group 4, CCD 21 (45) * 26 (27)
5 rPhl p 5b 47 (26) 12 (23) 35 (28) 4.83 (0.61–
28.58)
3.41 (0.32–
86.9)
Grass-group 5 11 (23) 32 (33)
6 rCan f 1 43 (24) 16 (30) 27 (21) 14.28 (0.44–
111.13)
6.91 (0.61–
121.54)
Lipocalin 16 (34) 25 (26)
7 rFel d 4 43 (24) 15 (28) 28 (22) 9.32 (0.45–
118.56)
2.9 (0.34–
55.56)
Lipocalin 15 (32) 27 (28)
8 rCan f 5 40 (22) 14 (26) 26 (21) 2.29 (0.54–
28.17)
3.62 (0.35–
27.48)
Arginine Esterase 14 (30) 23 (24)
9 rPhl p 6 35 (20) 12 (23) 23 (18) 0.89 (0.38–
14.56)
2.66 (0.36–
33.03)
Grass-group 5/6 11 (23) 21 (22)
10 nArt v 1 35 (20) 12 (23) 23 (18) 1.14 (0.34–
43.7)
1.39 (0.32–
38.99)
Defensin-like protein 12 (26) 21 (22)
11 rDer p 2 34 (19) 13 (25) 21 (17) 33.79 (0.57–
131.74)
5.18 (0.35–
103.86)
Group 2 mite-
allergen
12 (26) 20 (21)
12 rPhl p 2 31 (17) 6 (11) 25 (20) 9.72 (0.74–
27.15)
5.59 (0.36–
33.3)
Grass-group 2/3 5 (11) * 24 (25)
13 rCan f 6 26 (15) 10 (19) 16 (13) 2.11 (0.4–
14.01)
1.72 (0.3–
7.25)
Lipocalin 10 (21) 15 (16)
14 nDer p 1 25 (14) 11 (21) 14 (11) 4.99 (0.62–
18.63)
0.88 (0.4–
31.58)
Group 1 mite-
allergen
10 (21) 13 (14)
15 rCan f 2 25 (14) 9 (17) 16 (13) 1.03 (0.4–
49.04)
2.09 (0.34–
41)
Lipocalin 9 (19) 15 (16)
16 rDer p 4 18 (10) 10 (19) * 8 (6) 0.87 (0.32–
3.57)
0.71 (0.32–
4.87)
Group 4 mite-
allergen
9 (19) * 7 (7)
17 rDer p
23
18 (10) 7 (13) 11 (9) 29.98 (0.7–
98.11)
14.16 (1.69–
43.88)
Chitin-binding
domain
6 (13) 11 (12)
18 rCan f 4 14 (8) 6 (11) 8 (6) 8.65 (0.45–
64.14)
12.25 (0.39–
25.9)
Lipocalin 6 (13) 7 (7)
19 rDer p
10
12 (7) 8 (15) ** 4 (3) 0.49 (0.3–
3.8)
2.57 (0.44–
3.47)
Tropomyosin 7 (15) * 3 (3)
20 rDer p 5 11 (6) 6 (11) 5 (4) 1.48 (0.44–
93.01)
2.47 (0.34–
87.36)
Group 5 mite-
allergen
6 (13) 4 (4)
21 rDer p 7 9 (5) 4 (8) 5 (4) 1.82 (0.37–
3.71)
11.65 (0.75–
22.5)
Group 7 mite-
allergen
4 (9) 4 (4)
22 rDer p
11
8 (4) 4 (8) 4 (3) 0.42 (0.3–
1.62)
0.86 (0.31–
1.09)
Group 11 mite-
allergen
3 (6) 4 (4)
23 rDer p
15
5 (3) 3 (6) 2 (2) 0.33 (0.32–
16.44)
0.7 (0.68–
0.71)
Chitin-binding
domain
3 (6) 2 (2)
24 rDer p
21
6 (3) 3 (6) 3 (2) 2.52 (0.86–
71.48)
47.28 (11.23–
80.02)
Group 21 mite-
allergen
3 (6) 3 (3)
(Continued)
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The levels of allergen-specific IgE to the individual allergens expressed in ISU varied
between severe and moderate AD patients. For some allergens (e.g., rFel d 1) the IgE levels
were comparable and for others severe AD patients showed higher allergen-specific IgE levels
(e.g., rFel d 4, rDer p 2, rDer p 23) (Table 3).
An interesting finding was that the IgE reactivity profile of patients with severe AD was
more spread towards several different allergen molecules as compared to patients with moder-
ate AD (Fig 1B). The latter becomes visible when the contribution of the individual allergens to
IgE sensitization is displayed in the form of a pie chart where it becomes obvious that the seg-
ment of the 12 house dust mite allergens occupy a larger part, 26%, of the pie in severe AD
patients compared to 17% in moderate AD patients (Fig 1B). In contrast the contribution of
grass pollen allergens (i.e., rPhl p 1, rPhl p 2, rPhl p 5b and rPhl p 6) is lower in severe AD
patients 19% compared to 29% in the moderate AD group (Fig 1B).
Summary of allergen-specific IgE reactivities in the AD patients
Altogether, IgE reactivity as tested to 120 allergen components (MeDALL allergen chip), and
toM. sympodialis, S. aureus and human epithelial cell extracts (immunoblotting assays) was
detected in 92% of patients with severe and 83% of patients with moderate AD (Table 4). Six %
Table 3. (Continued)
No. Allergen All AD Severe
AD
Moderate
AD
Severe AD Moderate AD Allergen family,
Function, CCD
Severe AD Moderate AE
median
(range)
median
(range)
Rhinoconjuctivitis Rhinoconjuctivitis
n = 179 n = 53 n = 126 IgE (ISU)a) IgE (ISU) and/or asthma and/or asthma
n (%) n (%) n (%) n = 47 n (%) n = 96 n (%)
25 rDer p
18
6 (3) 2 (4) 4 (3) 3.76 (1.85–
5.67)
1.21 (0.32–
8.22)
Chitin-binding
domain
2 (4) 4 (4)
26 rDer p
14
4 (2) 1 (2) 3 (2) 0.68 (0.68) 0.56 (0.39–
1.28)
Vitellogenin 1 (2) 3 (3)
36 (77)
a) MeDALL allergen chip, reference range  0.3 ISU
Signiﬁcant differences between severe and moderate AD patients are indicated * p<0.05, ** p<0.01. Taken into account the number of tested variables
(n = 26) the expected number of allergens to be signiﬁcant at p level <0.05 by chance is 1.3.
AD = atopic dermatitis, CCD = cross-reactive carbohydrate determinates, n = natural, r = recombinant
doi:10.1371/journal.pone.0156077.t003
Table 4. Summary of allergen-specific IgE reactivities in the AD patients.
All AD Severe AD Moderate AD
IgE reactivity to the allergens/allergen components tested a) n = 179 n = 53 n = 126
n (n%) n (n%) n (n%)
Any allergen/allergen component 154 (86%) 49 (92%) 105 (83%)
Mono-sensitized b) 18 (10%) 3 (6%) 15 (12%)
Sensitized to 2–25 allergens/allergen components 109 (61%) 34 (64%) 75 (59%)
Sensitized to 26–55 allergens/allergen components 27 (15%) 12 (22%) 15 (12%)
a) Tested for IgE reactivity to 120 allergen components (MeDALL allergen chip), and to M. sympodialis, S. aureus and human epithelial cell extracts
(immunoblotting).
b) Mono-sensitised severe AD patients: M. sympodialis (n = 3)
Mono-sensitised moderate AD patients: Grass pollen (n = 2), birch pollen (1), dog (1), cat (5), house dust mite (1), M. sympodialis (4), wasp venom (1).
doi:10.1371/journal.pone.0156077.t004
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(n = 3) of the severe and 12% (n = 15) of the moderate AD patients were mono-sensitized. The
three patients in the severe group were all mono-sensitized toM. sympodialis whereas the sen-
sitization profile in the moderate group was spread over seven different allergen sources. The
majority of the patients were sensitized to 2–25 allergens/allergen components (Table 4). The
maximum number of allergens/allergen components detected in a patient in the severe group
was 55 and in the moderate group 48.
Discussion
In this study we used a comprehensive panel of allergen molecules from exogenous allergen
sources, microbes and autoantigens to characterize the molecular IgE reactivity profile of AD
patients with defined clinical phenotypes. We found that patients with severe differed from
patients with moderate AD regarding several characteristics. First, severe AD patients were
characterized by the fact that they reacted to a larger panel of environmental allergens than
patients with moderate AD. Interestingly, the spreading of the IgE recognition profiles in the
severe AD patients included allergens from certain environmental allergen sources such as
house dust mite, cat, and birch pollen allergens but not the major timothy grass pollen aller-
gens (Phl p 1, Phl p 5, Phl p 2 and Phl p 6) (Fig 1). This finding would suggest that grass
pollen allergens are less important as trigger factors for AD compared to birch pollen and
indoor allergens in the studied population. The difference between birch pollen and grass
pollen is unexpected because grass pollen contains several very potent allergens whereas
birch contains only one major allergen (Bet v 1). Furthermore, the grass pollen season lasts
longer than the birch pollen season and allergen loads are typically higher for grass pollen
[32,33]. Since the route of exposure should be the same for both pollens it is quite conceivable
that other factors play a role such as climatic effects where low humidity and cold tempera-
tures negatively affect skin barrier functions and increase the risk of dermatitis [34]. We
therefore hypothesize that an impaired skin barrier of patients after the usually long winter
periods in Sweden before the birch pollen season may be responsible for the fact that birch
pollen is associated more with severe AD whereas the skin barrier may regenerate towards
the later grass pollen season.
Secondly, patients suffering from severe AD also differed from patients with moderate AD
regarding their recognition of microbial “allergens” and autoantigens. IgE-reactivity to skin-
associated microorganisms likeM. sympodialis or S. aureus as well as to human antigens was
significantly higher in the severe AD group (Table 2). The percentage in all AD patients who
showed IgE-reactivity to theM. sympodialis extract, as detectable with ImmunoCap™ or immu-
noblot analyses, was 47–45%, which is in agreement with previous studies as is the high fre-
quency of head and neck involvement, particularly in the severe AD patients (S2 Table)
[15,35–37].
Regarding IgE reactivity to the 10 rMala s allergens using Dot blot analyses, the dominating
allergen was rMala s 13 (30%) which has sequence similarities to human thioredoxin [21]. Evi-
dence for T cell–mediated cross-reactivity between human thioredoxin, and Mala s 13 has been
demonstrated, suggesting that thioredoxin-autoreactive skin-homing T cells might contribute
to the pathogenesis of AD by perpetuating skin inflammation and chronification of eczema in
patients with AD sensitized toMalassezia [38]. The AD patients, who in addition to reactivity
to environmental allergens likeM. sympodialis, also have cross-reactivity to human counter-
parts, are highly interesting from a pathogenic aspect. Besides Mala s 13, Mala s 6 (a cyclophi-
lin), and Mala s 11 (a manganese-dependent superoxide dismutase) share a high degree of
sequence identity to the corresponding human enzymes (S1 Table) and might therefore play
an essential role in perpetuating skin inflammation of AD due to cross-reactivity. It is thus
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quite possible that IgE recognition of human homologous allergens may have been triggered by
sensitization to cross-reactive microbial allergens.
Different explanations for the broader and more spread allergen profile recognized by the
severe AD patients may be considered. On the one hand it is possible that the severity of AD
may depend on the number of different allergen molecules recognized and thus the sum of rec-
ognized allergens may play a role as has been recently reported for respiratory allergy to house
dust mites: Children with more severe respiratory manifestations (i.e., asthma plus rhinitis)
exhibited a broader IgE-recognition towards individual house dust mite allergens than children
suffering only from rhinitis [39]. This is similar to the findings made: We also found a broader
recognition of house dust mite allergens in the severe AD group as compared to the moderate
AD group (Table 3 and Fig 1). In this context, it has also been discovered that AD patients dif-
fer regarding their molecular recognition profiles of house dust mite allergens compared to
patients suffering only from house dust mite-associated respiratory allergy [40].
Alternatively, one may consider also other explanations. For example it may be considered
that patients with more severe AD and broader IgE recognition profiles may be more “atopic”
than the patients with moderate AD. It has been reported that patients with poly-sensitization
to respiratory allergens differed from patients with oligo/monosensitization by their produc-
tion of IL-4 and Th2 driving cytokines [41]. In this scenario which was recently suggested as a
hypothesis [42], a more “atopic” genetic make-up would be responsible for poly-sensitization
and for a more severe disease. This is in agreement with our study where besides having higher
IgE levels, more broadly spread sensitization pattern and higher frequency of IgE-reactivity,
91% of the AD patients in the severe group reported co-morbidity with respiratory allergic
symptoms compared with 76% in the moderate AD group (Table 1). Finally, one must con-
sider epigenetic modifications as additional factors for the development of different disease
phenotypes.
Another highly interesting subgroup of AD patients are those with a clinical picture of AD
but who lack detectable IgE antibodies to known allergens and have normal total serum IgE
levels. In the present study including all allergen components tested 13% of the AD patients
were found in this category (8% of patients with severe and 16% of patients with moderate
AD). At present, one may therefore define this group as “intrinsic” but it is possible that the
corresponding allergens triggering the skin inflammation in this group are not yet defined.
Alternatively, it is quite possible that these patients suffer from non-IgE-associated forms of
AD [43].
In summary, our study revealed a hitherto unknown difference regarding the molecular sen-
sitization profile in patients with severe and moderate AD. Molecular profiling towards aller-
gen components may thus provide a basis for future investigations aiming to explore the
environmental, genetic and epigenetic factors which could be responsible for the different
appearance and severity of disease phenotypes in AD leading to a platform for future preven-
tion and treatment strategies of different AD subgroups.
Supporting Information
S1 Fig. Concordance between total serum IgE, positive Phadiatop1 and specific serum IgE
toM. sympodialis extract using ImmunoCAP™. (A) 179 AD patients, (B) 53 severe AD
patients, and (C) 126 moderate AD patients.
(TIF)
S2 Fig. Frequencies and intensities of IgE reactivity to: (A), members of the PR-10 allergen
family, (B), animal allergens, (C), grass pollen allergens, (D), house dust mite allergens, (E),
plant pollen allergens, (F), cow’s milk and egg allergens, (G), nut allergens, and (H), latex and
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mould allergens in patients with severe (s), moderate (m) atopic dermatitis (AD) or sebor-
rhoeic eczema (SE) measured by allergen chip technology. Displayed are percentages (y-axes)
of sera containing IgE in the range of 0.3 to 0.99 ISU (white boxes), 1 to 15 ISU (grey) and>15
ISU (black) to the respective allergens (x-axes).
(TIF)
S1 Table. RecombinantM. sympodialis allergens used in this study.
(PDF)
S2 Table.M. sympodialis specific IgE reactivity in AD patients and controls.
(PDF)
S3 Table. Frequencies of IgE reactivity to purified allergens in AD patients and controls
detected by allergen chip technology.
(PDF)
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